comprehensive -WSS

comprehensive

author：entertainment 2025-09-14 10:07:48 - browse：222

Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Texas Department of Public Safety speaks out on migrant abuse allegations

hotspot

knowledge

WSS

Hospitals struggle to profit from CAR

Cancer researcher Catriona Jamieson is sending tumors into space

Exact Sciences stock tumbles despite strong cancer detection sales

Indian pharmaceutical industry in denial over drug

Stanford president faces new allegations over 1999 paper

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

hotspot

comprehensive

entertainment

Wildfire smoke exposes gaps in outdoor worker protections

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

After affirmative action ruling, medical educators look to 'holistic review'

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Sports medicine is finally prioritizing gender equality

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

23andMe had bad news about my health. I wish a person had delivered it

Tocagen's brain cancer gene therapy trial continues. Investors worry

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

focus

Study identifies new proteins linked to dementia risk 25 years later

Diversity in clinical trials starts with building trust, experts say

Vir antibody drug aimed at influenza A fails in clinical trial

Awakening the world to the whoosh: A patient's crusade

Ending racial health disparities hinges on penalties, political will

Tesla recalling nearly 16,000 of its 2021

focus

hotspot

knowledge

leisure time